Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Sanj K. Patel | CEO & Chairman of the Board | 1.57M | -- | 1969 |
| Mr. Eben Tessari | Senior VP & COO | 733.29k | -- | 1982 |
| Dr. John F. Paolini FACC, M.D., Ph.D. | Senior VP & Chief Medical Officer | 855.79k | -- | 1965 |
| Mr. Mark Ragosa C.F.A. | Senior VP & CFO | -- | -- | 1974 |
| Mr. Michael R. Megna CPA | Chief Accounting Officer & Group VP of Finance | -- | -- | 1971 |
| Ms. Mei Jang | Senior Vice President of Technical Operations | -- | -- | -- |
| Mr. Chad Morin | Senior VP & Chief Compliance Officer | -- | -- | -- |
| Ms. Madelyn Demsky Zeylikman | SVP, General Counsel & Secretary | -- | -- | 1974 |
| Mr. Carsten Boess M.B.A. | Executive Vice President of Corporate Affairs | -- | -- | 1966 |
| Ms. Martina Struck Ph.D. | Senior Vice President of Regulatory Affairs | -- | -- | -- |
Kiniksa Pharmaceuticals International, plc
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 297
Description
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Corporate Governance
Upcoming Events
October 29, 2024 at 11:30 AM UTC
Kiniksa Pharmaceuticals International, plc Earnings Date
Recent Events
July 23, 2024 at 12:00 AM UTC
15-15D/A: Notice of suspension of duty to file reports pursuant to Section 13 and 15(d) of the Act
July 2, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission